2017   2016   2015   2014   2013   2012   2011   2010   2009   2008  

11. November 2014
TG2 panel from animal species relevant as models for non-clinical safety testing
Document

28. October 2014
Zedira communication: Zedira to present at BioEurope® 2014: License opportunities in celiac disease and anticoagulation
Document

17. September 2014
Zedira supports the Meeting of American Society of Matrix Biology
Document

31. July 2014
Factor XIIIa inhibitor - Transglutaminase newsletter July-2014
Document

18. July 2014
Zedira communication: Publication on MTG Treatment in Pasta
Document

04. March 2014
Zedi's transglutaminase crossword puzzle winner is Greg Byrne
Document

03. March 2014
Zedira supports the Transglutaminase Session at the ASPET Annual Meeting at Experimental Biology 2014
Document

21. January 2014
Activated epidermal Transglutaminase (TG3) - Transglutaminase newsletter 1-2014
Document

03. January 2014
Zedira supports Gordon Research Conference on “Transglutaminases in Human Disease Processes: Molecular Dissection of Human Diseases Pathogenesis”
Document

  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland